Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response

Published:2022-09-06 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Storti Paola¹,Marchica Valentina¹,Vescovini Rosanna¹,Franceschi Valentina²,Russo Luca²,Notarfranchi Laura¹,Raimondi Vincenzo¹,Toscani Denise¹,Burroughs Garcia Jessica¹,Costa Federica³,Dalla Palma Benedetta⁴,Iannozzi Nicolas Thomas¹,Sammarelli Gabriella⁴,Donofrio Gaetano²,Giuliani Nicola¹⁴^ORCID

Affiliation:

1. Department of Medicine and Surgery, University of Parma, Parma, Italy

2. Department of Medical-Veterinary Science, University of Parma, Parma, Italy

3. School of Medicine, “Università del Piemonte Orientale”, Novara, Italy

4. Hematology, “Azienda Ospedaliero-Universitaria di Parma”, Parma, Italy

Funder

International Myeloma Society

“Paula and Rodeger Riney Foundation Translational Research Grant”

Associazione Italiana contro Leucemie, Linfomi e Mielomi ONLUS, ParmAIL

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2120275

Reference48 articles.

1. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance

2. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

3. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study

4. Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

5. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of BoHV-4-based vector vaccine intranasally administered in a hamster challenge model of lung disease;Frontiers in Immunology;2023-07-06

2. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study;Swiss Medical Weekly;2023-06-15

3. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN);Leukemia;2023-05-04

4. Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis;Cancers;2023-04-12

5. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study;Viruses;2023-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3